What question did this study set out to answer?

To assess whether fixed-dose subcutaneous certoparin without body-weight adjustment is as effective and safe as dose-adjusted intravenous unfractionated heparin for initial therapy of proximal deep-vein thrombosis.

January 1, 2000Thrombosis and Haemostasis

Fixed-dose, Body Weight-independent Subcutaneous LMW Heparin versus Adjusted Dose Unfractionated Intravenous Heparin in the Initial Treatment of Proximal Venous Thrombosis

View Full Paper

Ask AI

Bookmark

Authors

JSJens-Ove SchmidtKolding Hospital KKK. KoppenhagenFranklin University ATA. TolleTwitter (United States)

Discussion

Member takes

Implication

Randomized trial demonstrates lower complication rates with fixed-dose certoparin than unfractionated heparin in proximal deep-vein thrombosis, highlighting a simplified treatment option.

Key Points

To assess whether fixed-dose subcutaneous certoparin without body-weight adjustment is as effective and safe as dose-adjusted intravenous unfractionated heparin for initial therapy of proximal deep-vein thrombosis.
Randomized trial allocating patients with confirmed proximal deep-vein thrombosis to fixed-dose subcutaneous certoparin (8,000 anti-Xa U twice daily; n=265) or dose-adjusted intravenous unfractionated heparin (n=273) for 12 days.
Vitamin K antagonists were initiated between days 3 and 7 and maintained for up to 6 months.
The primary endpoint was a ≥30% improvement in Marder score evaluated by repeat venography on day 12; secondary outcomes included a blinded composite of death, recurrent thromboembolism, and major bleeding at day 12 and 6 months.
A ≥30% improvement in the Marder score occurred in 30.3% of the certoparin group (60/198 paired venograms) versus 25.0% of the unfractionated heparin group (48/192 paired venograms; 2p = 0.26).
The composite safety and efficacy endpoint at day 12 occurred in 1.5% (4/265) of certoparin patients compared with 5.1% (14/273) of unfractionated heparin patients (2p = 0.03).
At 6 months, composite events were significantly lower with certoparin at 6.8% versus 12.8% with unfractionated heparin (risk reduction 0.53, 95% CI 0.31–0.90, 2p = 0.02).

Cite This Study

Schmidt et al. (2000) studied this question.

synapsesocial.com/papers/6a7d8e96f3499a80f78c8fdd https://doi.org/10.1055/s-0037-1613886

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates lower complication rates with fixed-dose certoparin than unfractionated heparin in proximal deep-vein thrombosis, highlighting a simplified treatment option.

Fixed-dose, Body Weight-independent Subcutaneous LMW Heparin versus Adjusted Dose Unfractionated Intravenous Heparin in the Initial Treatment of Proximal Venous Thrombosis

Discussion

Member takes

Implication

Key Points

Cite This Study

Fixed-dose, Body Weight-independent Subcutaneous LMW Heparin versus Adjusted Dose Unfractionated Intravenous Heparin in the Initial Treatment of Proximal Venous Thrombosis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider